 | | Vol. 12.37 – 1 October, 2021 |
| |
|
|
| Scientists observed that DU145 prostate and NCI–H2228 lung cancer cells were resistant to the cytotoxic effect of rapamycin.
[Cancer Letters] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors showed that CDK9 inhibition resulted in the loss of androgen receptor (AR) and AR-v7 expression due to the defects in splicing, which sensitized castration-resistant prostate cancer cells to androgen deprivation.
[RNA Biology] |
|
|
|
| Scientists investigated differences in cytotoxicity and mechanisms between LMW-IR700 and Ab-IR700 targeting prostate-specific membrane antigen.
[International Journal of Pharmaceutics] |
|
|
|
| Researchers used screening tests for candidate drugs targeting cabazitaxel (CBZ)-resistant-related gene expression and identified pimozide as a potential candidate for overcoming CBZ resistance in castration-resistant prostate cancer.
[Prostate Cancer and Prostatic Diseases] |
|
|
|
| The authors designed and synthesized a new prostate-specific membrane antigen-targeted radiotracer, 68Ga-SC691, with high affinity for prostate cancer cells and excellent pharmacokinetics.
[Scientific Reports] |
|
|
|
| Researchers analyzed the effect of curcumol on prostate cancer and identify its possible internal regulatory pathway using in vitro cell culture and in vivo tumor model experiments.
[Oncology Reports] |
|
|
|
| NCAPD3 is an androgen/AR axis-targeted gene and is involved in androgen receptor (AR)-induced prostate cancer (PCa) cell proliferation, migration, and invasion in vitro and in vivo. Androgen treatment and AR overexpression increased the expression of NCAPD3 in PCa cell lines.
[Prostate] |
|
|
|
| Using orthogonal flow cytometry analysis, scientists demonstrated that primary patient-derived cancer organoid maintain distinct subsets of epithelial cells throughout culture and that these cells conserve expression of androgen receptor-related elements.
[Medical Oncology] |
|
|
|
| Researchers observed that bergamottin reduced prostate cancer cell growth by decreasing both total and nuclear AR reducing downstream AR signaling.
[PLOS One] |
|
|
|
| Among the compounds tested, compounds 9i and 9k potently arrested proliferation of DU-145, the prostate cancer cell line.
[Natural Product Research] |
|
|
|
|
| Scientists evaluate the advances in 3D culture and patient derived organoid (PDO) use to model clonal heterogeneity and screen for effective targeted therapies, with a focus on the technological advances in generating PDOs.
[Molecular Cancer] |
|
|
|
| The authors discuss the current understanding of the immunogenic stress pathways in cancer and describes the interrelation between extracellular vesicles and immunogenic stress to propose potential treatment strategies and biomarkers.
[Cell Death & Disease] |
|
|
|
|
| AstraZeneca and Merck & Co., Inc. announced positive high-level results from the PROpel Phase III trial.
[AstraZeneca, Inc. (BusinessWire, Inc.)] |
|
|
|
|
| November 1 – 3, 2021
Virtual |
|
|
|
|
|
| | University of California San Francisco – San Francisco, California, United States |
|
|
|
| | The University of New Mexico – Albuquerque, New Mexico, United States |
|
|
|
| | Houston Methodist Research Institute – Houston, Texas, United States |
|
|
|
| | Zhejiang University School of Medicine – Hangzhou, China |
|
|
|
| | Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
